Targeted therapies and immunotherapy can provide benefits when added to chemotherapy or may eliminate the need for ...

Partial nephrectomy preserves renal function better than radical nephrectomy for complex tumors, especially in younger ...

A potential $4 billion licensing deal with Vor Bio triggered a slide in RemeGen's stock price. Otsuka obtained a BCMAXCD3 ...

In May 2025, the Journal for ImmunoTherapy of Cancer published a pioneering study entitled "NeoPred: dual-phase CT AI forecasts pathologic response to ...

Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, explains how the company partners with patient advocacy groups to identify unmet needs and prioritize patient-centered benefits in the ...

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

The company said the therapy is the first allogenic therapy developed with its Tmod technology to be tested in humans.

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to DATROWAY® (datopotamab deruxtecan-dlnk) for ...

The firm is also considering a US regulatory submission of its QiAcuityDx system along with a companion diagnostic test.